Gilead Sciences, Inc. $GILD Shares Sold by BridgePort Financial Solutions LLC

BridgePort Financial Solutions LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 51.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,444 shares of the biopharmaceutical company’s stock after selling 3,610 shares during the period. BridgePort Financial Solutions LLC’s holdings in Gilead Sciences were worth $382,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Howard Hughes Medical Institute acquired a new stake in Gilead Sciences during the second quarter worth approximately $30,000. Finally, Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. The trade was a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the insider directly owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 319,391 shares of company stock valued at $44,141,101. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 2.9%

Shares of Gilead Sciences stock opened at $147.23 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $153.13. The stock has a market cap of $182.67 billion, a price-to-earnings ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a fifty day moving average price of $128.39 and a 200 day moving average price of $121.53.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same quarter in the previous year, the firm posted $1.90 earnings per share. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.2%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. Gilead Sciences’s dividend payout ratio is 48.99%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Sanford C. Bernstein set a $135.00 price target on Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Mizuho increased their target price on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, January 13th. Finally, Citigroup raised their target price on shares of Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $136.73.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat estimates: Gilead reported $1.86 EPS vs. a $1.83 consensus and revenue rose ~4.7% YoY, helping demonstrate underlying portfolio resilience. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Dividend bump: Board raised the quarterly dividend by 3.8% to $0.82, supporting the stock’s income profile for yield‑focused investors. Gilead Sciences Announces 3.8% Dividend Increase
• Positive Sentiment: Pipeline and product momentum: Management cited growth in liver‑disease and HIV franchises and potential launches (including additional HIV options and two cancer therapy filings/approvals) and analysts remain upbeat on launches like Yeztugo. These could underpin medium‑term growth. WSJ: Gilead Profit Rises on Liver Disease, HIV Products Seeking Alpha: Q4 Preview
• Neutral Sentiment: Official earnings release and slide deck available for review — useful for digging into product-level trends and guidance assumptions. MarketWatch: Q4 and Full-Year Results
• Neutral Sentiment: Reported short‑interest data in filings is effectively meaningless/garbled for the period cited (shows 0 shares), so it provides no clear near‑term pressure signal.
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–$8.85 sits at the low end of Street forecasts and revenue guidance ($29.6–$30.0B) came in below consensus — the primary driver of the stock’s pullback as investors re‑price growth expectations. Benzinga: Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
• Negative Sentiment: Analyst/headline pushback: Several outlets flagged that the light outlook could weigh on the stock despite a clean beat, amplifying downward pressure in the session. Investor’s Business Daily: Light Outlook May Hurt Stock Reuters: Beat but Light Forecast
• Negative Sentiment: Insider selling: CEO disclosed a roughly $17.3M stock sale recently, which some investors view negatively even if driven by personal liquidity. AmericanBankingNews: CEO Stock Sale

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.